Eczema drug trial halted early: what we know

NCT ID NCT05984784

Terminated Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and whether it improves eczema symptoms. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AD ATOPIC DERMATITIS MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Locations

Amicis Research Center

Northridge, California, 91324, United States
Amicis Research Center

Valencia, California, 91355, United States
Brunswick Dermatology Center

Fredericton, New Brunswick, E3B 1G9, Canada
Central Sooner Research

Oklahoma City, Oklahoma, 73170, United States
Centre de Recherche Saint-Louis (Québec)

Québec, G1W4R4, Canada
DermEffects

London, Ontario, N6H 5L5, Canada
Markowitz Medical, LLC

New York, New York, 10128, United States
Medical Research Center of Miami II Inc

Miami, Florida, 33134, United States
Optimal Research Sites

Orange City, Florida, 32763, United States
Paddington Testing Co, Inc

Philadelphia, Pennsylvania, 19103, United States
Revival Research Institute, LLC

Troy, Michigan, 48084, United States
USF Carol and Frank Morsani Center for Advanced Healthcare

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.